Precision Immunology Is Trying to End the Guesswork

Immunology has produced a wave of powerful therapies over the past decade, but treatment selection still feels surprisingly imprecise. Many patients cycle through multiple drugs before finding one that works, even in diseases where biologic therapies are well established. For healthcare systems, payers and biotechnology companies, that process creates a familiar set of problems: wasted time, rising costs, frustrated physicians and patients losing confidence while symptoms continue.

The issue is no longer whether therapies can work. The harder question is figuring out which patients are actually likely to respond before treatment begins.That sounds straightforward in theory, but immune diseases rarely behave in simple ways. Two patients with the same diagnosis can respond very differently to the exact same therapy. A single biomarker often fails to explain why. Immune response is usually shaped by overlapping molecular signals, clinical history and biological patterns that do not fit neatly into one test result or one mutation profile.

That complexity has made precision immunology harder than many people expected. It is also why therapy-selection platforms are getting more attention from both pharmaceutical companies and healthcare providers. The real value is not in producing more biological data for its own sake. It is in turning that data into practical treatment decisions that physicians can actually use.

Strong platforms tend to focus on response prediction rather than broad disease categorization. Instead of asking whether a therapy works generally, they try to identify which patients are unlikely to benefit and which ones have a stronger probability of response. That distinction matters because it changes what happens next. In clinical practice, it can reduce months of trial-and-error prescribing. In drug development, it can help sponsors build trials around populations more likely to show efficacy signals.

The evidence behind the arguments is, of course, key. Medical prediction is already drowning in predictive language and backward explanation, and healthcare systems are growing wary of the seemingly impressive models that don't obviously improve treatment. The better approaches correlate biological understanding with actual, subsequent action in the clinic. Where an algorithm predicts that a patient will respond poorly to a treatment, a physician needs a new direction in which to take them, not just more layers of explanation.

Drug developers are paying attention for the same reason. Failed immunology trials are expensive, especially when large populations are enrolled without a clear understanding of which patients are biologically aligned with the therapy. More companies are now looking at molecular stratification earlier in development, both to improve trial design and to strengthen eventual companion diagnostic strategies.

Scipher Medicine has built its approach around that shift toward response-based immunology. Its PrismRA test is a blood-based molecular signature response classifier designed for rheumatoid arthritis patients, helping predict inadequate response to TNF inhibitor therapies. The platform combines gene expression data, clinical features and anti-CCP antibody information through a 23-feature model aimed at identifying likely non-responders before treatment escalation begins. The company is also applying its network medicine platform to companion diagnostic development and broader response segmentation efforts in immunology. For healthcare organizations and drug developers trying to reduce the inefficiency of trial-and-error prescribing, that kind of patient selection model is becoming harder to ignore.